Crysvita Evropska unija - slovenščina - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - zdravila za zdravljenje bolezni kosti - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

OsteoD 0,25 mikrograma mehke kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

osteod 0,25 mikrograma mehke kapsule

teva pharma b.v. - kalcitriol - kapsula, mehka - kalcitriol 0,25 µg / 1 kapsula - kalcitriol

OsteoD 0,5 mikrograma mehke kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

osteod 0,5 mikrograma mehke kapsule

teva pharma b.v. - kalcitriol - kapsula, mehka - kalcitriol 0,5 µg / 1 kapsula - kalcitriol

Kalcijev karbonat Krka 1 g tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kalcijev karbonat krka 1 g tablete

krka, d.d., novo mesto - kalcijev karbonat - tableta - kalcijev karbonat 1 g / 1 tableta - kalcijev karbonat